FDA Approved: LETAIRIS — Original Application (Gilead Sciences, Inc.)

View source ↗

Summary

The FDA approves LETAIRIS (ambrisentan) in an original application from Gilead Sciences for the treatment of pulmonary arterial hypertension. This marks the ori…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• LETAIRIS (ambrisentan)

Snippet

ORIG AP for LETAIRIS (AMBRISENTAN)